icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
zd7A8MdqZkDg4mC8